Lorigerlimab (NCT05475171)

Name: Lorigerlimab trial for Metastatic Cancer (NCT05475171)
Uploaded: 2026-10-31T22:31:34.547Z
Duration: 1 min 15 s
Description: Lorigerlimab trial for Metastatic Cancer (NCT05475171). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05475171.

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION): a one-minute explainerNCT054751711 min

Lorigerlimab trial for Metastatic Cancer (NCT05475171). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with recurrent, metastatic or persistent cervical cancer that cannot receive curative treatment. Eligible types are squamous, adenosquamous and adenocarcinoma. Prior chemotherapy is allowed only with radiation; prior checkpoint immunotherapy is excluded.

The idea: intravenous lorigerlimab blocks PD-1 and CTLA-4, two brakes on immune cells. Researchers study cancer control, survival and side effects. The record does not specify the dose or cycle length.

This phase 2 study plans 60 patients. Amir Jazeri leads it at MD Anderson in Houston, the single recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.